Neurogenetics and clinical evidence for the putative activation of the brain reward circuitry by a neuroadaptagen: proposing an addiction candidate gene panel map.
about
Sex, drugs, and rock 'n' roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphismsDopamine and glucose, obesity, and reward deficiency syndromeNeuropsychopharmacology and neurogenetic aspects of executive functioning: should reward gene polymorphisms constitute a diagnostic tool to identify individuals at risk for impaired judgment?Early intervention of intravenous KB220IV--neuroadaptagen amino-acid therapy (NAAT) improves behavioral outcomes in a residential addiction treatment program: a pilot study.Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric.Broad-spectrum micronutrient formulas for the treatment of psychiatric symptoms: a systematic review.The Molecular Neurobiology of Twelve Steps Program & Fellowship: Connecting the Dots for Recovery.Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?Diagnosis and Healing In Veterans Suspected of Suffering from Post-Traumatic Stress Disorder (PTSD) Using Reward Gene Testing and Reward Circuitry Natural Dopaminergic ActivationNeuropsychiatric Genetics of Happiness, Friendships, and Politics: Hypothesizing Homophily ("Birds of a Feather Flock Together") as a Function of Reward Gene PolymorphismsCan the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts.Have We Hatched the Addiction Egg: Reward Deficiency Syndrome Solution System™Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note.Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence.The addictive brain: all roads lead to dopamine.Efficacy and cost of micronutrient treatment of childhood psychosis.Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality.Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).Hypothesizing that a Pro-Dopaminergic Regulator (KB220z™ Liquid Variant) can Induce "Dopamine Homeostasis" and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence.Drug abuse relapse rates linked to level of education: can we repair hypodopaminergic-induced cognitive decline with nutrient therapy?Use of micronutrients attenuates cannabis and nicotine abuse as evidenced from a reversal design: a case study.Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake.The Emerging Field of Nutritional Mental Health
P2860
Q22248047-9F63F353-69C9-4237-A188-C08B63A19D54Q27003334-D67B462B-61AC-4D72-BB85-A70E83A51032Q27024858-81D30301-AF1D-4561-BB06-26710CFCC7F9Q33818454-BDA7182D-9DB3-4089-9DBF-186CC6F493EAQ34304684-CE302746-F181-4C63-B0B2-1467277977E1Q34318546-D21FFEFA-AC95-4889-8CCB-F86EE2CBBE6DQ34490946-64C67649-7494-4365-8CEE-77D2FCF03456Q36100262-68E8FAFA-EE88-428A-9712-9A82D6D58F1FQ36476988-91281ABD-5C79-4BBE-AFFA-ED91244AA173Q36541437-1C4A51F8-C2E6-43D4-8432-D462CEC470D9Q36928874-8DF77770-3F35-439D-8233-B3D46B0B6F61Q37069544-87CBD4FE-1F15-4497-8E31-DD7CDBE45339Q37164595-A1CAF42E-14B8-4A29-BB59-6AB830870BAFQ37198159-72C5EE54-3C3F-44AE-8C30-C0CAA6E810B3Q37329865-DED62C5A-84C4-4DA1-A237-5D8449F2943EQ37625198-EC2ADFB7-D917-45D8-A413-70046747D59DQ38033573-1EE78F20-32D2-4DFC-AB9F-D7E189861B22Q38059199-60CB4FA5-CCC0-450A-8571-88F814E57E40Q38568452-1DAFDA89-AD32-4A15-87E5-05084B03ED97Q39053008-3CFB48BE-9451-40BE-B89D-DDE664577491Q42375786-0D871A61-68B7-4265-A46A-0577AF3D5576Q44467061-BFF1F50C-555C-4DA7-AE1D-FE7C22C2A3DEQ44500090-ABB31EF3-06D2-4A58-AB86-A2C672EF3802Q47142976-EA29FF3D-7CC6-424F-A6B4-ECB935501D4EQ56675883-8034DBC7-F89E-4FFC-9B50-B41BC599AF31
P2860
Neurogenetics and clinical evidence for the putative activation of the brain reward circuitry by a neuroadaptagen: proposing an addiction candidate gene panel map.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Neurogenetics and clinical evi ...... tion candidate gene panel map.
@en
Neurogenetics and clinical evi ...... tion candidate gene panel map.
@nl
type
label
Neurogenetics and clinical evi ...... tion candidate gene panel map.
@en
Neurogenetics and clinical evi ...... tion candidate gene panel map.
@nl
prefLabel
Neurogenetics and clinical evi ...... tion candidate gene panel map.
@en
Neurogenetics and clinical evi ...... tion candidate gene panel map.
@nl
P2093
P2860
P1476
Neurogenetics and clinical evi ...... tion candidate gene panel map.
@en
P2093
Abdalla Bowirrat
Amanda L C Chen
David Miller
Eric R Braverman
Frank Fornari
John A Bailey
John Giordano
Kenneth Blum
Mallory Kerner
Margret A Madigan
P2860
P304
P356
10.1080/02791072.2011.587393
P577
2011-04-01T00:00:00Z